IPO13 Antikörper (AA 501-700) (HRP)

Produktnummer ABIN7156145

Produktdetails anti-IPO13 Antikörper (HRP)

Target: IPO13 (Importin 13 (IPO13))

Bindungsspezifität: AA 501-700

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IPO13 Antikörper ist konjugiert mit HRP

Applikation: ELISA

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Importin-13 protein (501-700AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu IPO13

Target: IPO13 (Importin 13 (IPO13))

Andere Bezeichnung: IPO13 (IPO13 Produkte)

Synonyme: 3R23 antikoerper, CG 7212 antikoerper, CG7212 antikoerper, Dmel\\CG7212 antikoerper, Imp13 antikoerper, imp13 antikoerper, sd-5 antikoerper, DDBDRAFT_0205767 antikoerper, DDBDRAFT_0304414 antikoerper, DDB_0205767 antikoerper, DDB_0304414 antikoerper, DDBDRAFT_0191787 antikoerper, DDBDRAFT_0304413 antikoerper, DDB_0191787 antikoerper, DDB_0304413 antikoerper, IMP13 antikoerper, KAP13 antikoerper, LGL2 antikoerper, RANBP13 antikoerper, Kap13 antikoerper, Ranbp13 antikoerper, Lgl2 antikoerper, DKFZp459H088 antikoerper, cadmus antikoerper, importin 13 antikoerper, cdm antikoerper, IPO13 antikoerper, AFUA_5G08060 antikoerper, ANI_1_1340034 antikoerper, AOR_1_1272114 antikoerper, ipo13B antikoerper, ipo13A antikoerper, ipo13 antikoerper, Ipo13 antikoerper

Hintergrund:

Background: Functions in nuclear protein import as nuclear transport receptor. Serves as receptor for nuclear localization signals (NLS) in cargo substrates. Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Mediates the nuclear import of UBC9, the RBM8A/MAGOH complex, PAX6 and probably other members of the paired homeobox family. Also mediates nuclear export of eIF-1A, and the cytoplasmic release of eIF-1A is triggered by the loading of import substrates onto IPO13.

Aliases: Imp 13 antibody, Imp13 antibody, Importin-13 antibody, Importin13 antibody, IPO 13 antibody, Ipo13 antibody, IPO13_HUMAN antibody, Kap 13 antibody, Kap13 antibody, Karyopherin 13 antibody, Karyopherin-13 antibody, Karyopherin13 antibody, KIAA0274 antibody, Late gestation lung 2 antibody, Late gestation lung 2 protein antibody, Lgl2 antibody, Ran binding protein 13 antibody, Ran-binding protein 13 antibody, RanBP 13 antibody, RanBP13 antibody

UniProt: O94829

Pathways: Intracellular Steroid Hormone Receptor Signaling Pathway, Nuclear Hormone Receptor Binding, Protein targeting to Nucleus